Piper Jaffray & Co. downgrades Simcere Pharmaceutical (NYSE: SCR) to Neutral. Price target $9.

Piper analyst says, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE